Upadacitinib (Rinvoq) for alopecia areata: what the 2026 phase 3 trials found and what it means in Malaysia

What the 2026 phase 3 UP-AA trials found for upadacitinib (Rinvoq) in severe alopecia areata, how the JAK1 tablet works, its EU approval and pending US review, side effects and safety checks, how it compares with other options and what Malaysians should ask a dermatologist.

Rambut editorial team ·

Alopecia areata can turn a normal morning into a shock: a smooth, round bald patch found by a barber, a partner or a hairdresser, or eyebrows and eyelashes that thin out within weeks. For people with the severe form, where half or more of the scalp hair is gone, the options used to be limited and unpredictable. Over the past few years a group of tablets called JAK inhibitors has changed that picture, and in 2026 a newer member of the group, upadacitinib, published large phase 3 results in alopecia areata.

This guide explains what upadacitinib is, how it acts on the immune attack behind alopecia areata, what the two UP-AA trials actually found, where it stands with regulators, the side effects and safety checks, how it compares with other options, and what a Malaysian reading this should realistically do next. It is general information, not personal medical advice, and it does not replace an appointment with a dermatologist. For background, see alopecia areata (patchy hair loss), JAK inhibitors for alopecia areata and whether alopecia areata can go away on its own.

The short answer

Upadacitinib is an oral JAK inhibitor that is already approved for several inflammatory diseases. In two phase 3 trials of 1,399 adults and adolescents with severe alopecia areata, about 45% of people on 15 mg and about 55% on 30 mg reached at least 80% scalp hair coverage after 24 weeks, against 1.5% to 3.4% on placebo 1. The European Union approved it for severe alopecia areata in July 2026, while the United States review was still pending 2. It is a prescription medicine with real risks, it does not switch the condition off for good, and hair loss can return if treatment stops. Whether and how it can be prescribed for alopecia areata in Malaysia is a question for a dermatologist, not a pharmacy shelf.

Alopecia areata in plain language

Alopecia areata is an autoimmune condition: the immune system mistakenly attacks hair follicles, which makes hair fall out, often in round patches 3. It can affect the scalp, beard, eyebrows, eyelashes and body hair. In some people it spreads to the whole scalp (alopecia totalis) or the whole body (alopecia universalis) 4.

The key point is that alopecia areata is usually non-scarring. The follicle is inflamed and pushed into a resting state, but it is not destroyed, so hair can grow back when the attack settles 5 6. This is why small patches often recover without treatment, and why medicines that calm the immune attack can work even after years of loss. It also explains the unpredictability: the condition can come and go, and a new episode can start after a period of full hair.

Doctors grade severity with the Severity of Alopecia Tool, or SALT score, which estimates the percentage of scalp hair lost. A SALT score of 50 means about half the scalp is bare; SALT 100 means the whole scalp. Trials for severe alopecia areata usually enrol people with SALT 50 or more, and they count success as reaching SALT 20 or less, meaning at least 80% of the scalp is covered 1.

How upadacitinib works

Healthy hair follicles in the growth phase normally hide from the immune system, a protection researchers call immune privilege. In alopecia areata that protection breaks down. Immune cells gather around the bulb of the follicle (often described as a "swarm of bees" under the microscope), and signalling molecules such as interferon-gamma and interleukin-15 keep the attack going 7 6.

Many of these signals pass into cells through enzymes called Janus kinases (JAK1, JAK2, JAK3 and TYK2). JAK inhibitors block those enzymes, so the inflammatory message is muted and the follicle can return to the growth phase 7. Upadacitinib is designed to act mainly on JAK1. Baricitinib acts on JAK1 and JAK2, and ritlecitinib acts on JAK3 and a related family of enzymes, so each medicine in the group has a slightly different profile 7 8 9.

Two things follow from this mechanism. First, the drug does not create new follicles; it lets existing, dormant follicles work again. Second, it treats the immune process rather than resetting it, so when the medicine stops, the attack can return.

What the UP-AA trials found

The results come from two matching phase 3 trials, UP-AA1 and UP-AA2, published in JAMA Dermatology in August 2026 1.

  • Who took part: 1,399 people aged 12 to under 64 with severe alopecia areata (SALT 50 or more), including 1,281 adults and 118 adolescents. The average SALT score at the start was 83.9, and about half had near-total or total scalp loss 1 10.
  • Design: people were randomly assigned to upadacitinib 15 mg, 30 mg or placebo once daily for 24 weeks, followed by a blinded extension to week 52 1.
  • Main result at week 24: SALT 20 or less was reached by 45.2% and 44.6% on 15 mg, 55.0% and 54.3% on 30 mg, and 1.5% and 3.4% on placebo in the two trials 1.
  • Full scalp coverage (SALT 0) at week 24: roughly 13% to 14% on 15 mg and 20% to 23% on 30 mg, against 0% to 0.7% on placebo 2.
  • Week 52: response rates kept rising during the extension, and full scalp coverage reached roughly 27% to 37% across doses 2 11.
  • Eyebrows, eyelashes and quality of life also improved more than with placebo 1.

Put simply, about half of people with severe, often long-standing alopecia areata had most of their scalp covered after six months, and a smaller group had full coverage. The other half did not reach that goal in the trial period, so a good response is likely but far from certain.

Where upadacitinib stands with regulators

Upadacitinib is sold as Rinvoq and is already approved in many countries for conditions such as rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, ulcerative colitis and Crohn's disease 11. For alopecia areata:

  • European Union: approved on 29 July 2026 for adults and adolescents aged 12 and over with severe alopecia areata, at 15 mg and 30 mg once daily 2.
  • United States: the manufacturer filed for the new use in April 2026, and the review was still pending at the time of writing 10 2. Three other JAK inhibitors are already approved there for severe alopecia areata: baricitinib, ritlecitinib and deuruxolitinib 11.
  • Malaysia: registration of a medicine and each approved use is handled by the National Pharmaceutical Regulatory Agency. You can look up registered products on its QUEST search 12, but the approved uses on a local label, and whether a doctor would prescribe a medicine outside them, are matters to discuss with a dermatologist. Rambut has not seen a Malaysian approval for this use, so treat it as something to ask about, not something to expect.

Side effects and safety checks

JAK inhibitors are powerful immune medicines, so the safety conversation matters as much as the hair results.

What the alopecia trials showed. Through week 24, side effects were reported by 62.7% on 15 mg and 67.1% on 30 mg, compared with 57.1% on placebo. The most common were upper respiratory tract infections, acne, a rise in a muscle enzyme called creatine phosphokinase on blood tests, and colds. Serious side effects occurred in 1.6% on 15 mg, 2.3% on 30 mg and 0.4% on placebo 1 11. The trial safety profile matched what is known from other uses, with no new safety signals 1.

The class warning. In 2021, the US Food and Drug Administration required boxed warnings for JAK inhibitors, including upadacitinib, about higher risks of serious heart-related events, cancer, blood clots and death, based on a large safety study in older people with rheumatoid arthritis and other risk factors 13. People with alopecia areata are often younger and healthier than that group, but the warning is the reason doctors screen carefully and choose the lowest effective dose.

Typical checks before and during treatment. A dermatologist will usually ask about infections, heart disease, blood clots, cancer history, smoking and pregnancy plans, and order baseline blood tests and screening for tuberculosis and hepatitis, then repeat some tests during treatment 7. Live vaccines are generally avoided while on JAK inhibitors, so vaccinations may need to be updated before starting. Upadacitinib is not used during pregnancy, and contraception is part of the discussion for anyone who could become pregnant.

How it compares with other options

OptionHow it worksBest suited toEvidenceMain drawbacks
Watchful waitingMany small patches settle on their ownOne or a few small patchesNatural history dataUnpredictable, can spread
Steroid injections into patchesCalms inflammation locallyLimited patchy diseaseLong clinical useRepeated injections, skin thinning, not practical for large areas
Topical steroids or contact immunotherapyLocal anti-inflammatory or immune redirectionPatchy disease, childrenMixed, smaller studiesSlow, irritation
Baricitinib or ritlecitinib (oral JAK inhibitors)Blocks JAK signallingSevere diseasePhase 3 trials, approved in several countriesClass safety warning, ongoing cost, relapse on stopping
Upadacitinib (oral JAK1 inhibitor)Blocks mainly JAK1 signallingSevere disease in adults and adolescentsTwo phase 3 trials, EU approval 2026Class safety warning, acne, infections, relapse on stopping
SMP, wigs and hair systemsCamouflage, no effect on the diseaseAnyone, alongside or instead of medicineCosmeticDoes not change hair growth; SMP needs stable patches

Sources for the medical options: 14 15 8 9 1. See also steroid injections for alopecia areata, SMP for alopecia areata and wigs and hair systems.

There is no head-to-head trial comparing upadacitinib directly with baricitinib or ritlecitinib, so claims that one is clearly "the best" go beyond the evidence. Cross-trial comparisons are tempting, but the trials enrolled different people and measured at different points.

What to expect, step by step

  1. Confirm the diagnosis. Patchy hair loss can also come from fungal infection, hair pulling, traction or scarring conditions. A dermatologist uses examination, trichoscopy and sometimes blood tests or a biopsy 14.
  2. Measure severity. Photos and a SALT score give a baseline, which matters because JAK inhibitors are generally aimed at severe disease.
  3. Screening tests. Blood tests, infection screening and a review of other medicines and health conditions.
  4. Starting treatment. One tablet a day at the dose your doctor chooses.
  5. The first three months. Fine hairs may appear in some areas first; in the trials, differences from placebo were visible by week 8 for many people 1. Others need longer.
  6. Around six months. This is when the main trial result was measured. Your doctor will judge whether the response is worth the ongoing risks and cost.
  7. Long term. If hair grows well, the conversation turns to how long to continue and whether the dose can be lowered. Stopping often leads to hair loss returning, so changes should be planned with the doctor, not done abruptly on your own 7.

Pros, cons and risks at a glance

Pros: a once-daily tablet; strong results in severe, long-standing disease; improvements in eyebrows and eyelashes; quality-of-life benefits; two large, well-designed trials behind it.

Cons: not everyone responds; benefits usually last only while treatment continues; regular blood tests; likely high ongoing cost; not yet approved for this use in every country.

Risks: infections, acne, laboratory changes and, under the class warning, rarer but serious events such as blood clots, heart problems and cancer 13. These risks must be weighed against how much the hair loss affects your life.

The Malaysian context

  • Who to see: alopecia areata is a medical condition. A dermatologist, at a government hospital through referral or privately, is the right person to discuss JAK inhibitors. The Dermatological Society of Malaysia lists information about the specialty 16.
  • Cost: Rambut has no verified Malaysian price for upadacitinib in alopecia areata, so ask for a written estimate that includes tests and follow-up visits. Treat any offer that skips screening or sells JAK inhibitors without a prescription as a red flag.
  • Climate and daily life: heat and humidity do not cause alopecia areata, but patches on a sweaty scalp burn easily in the sun. A cap, a tudung or sunscreen on bare patches helps comfort while waiting for treatment to work.
  • Mental health: sudden patches can be distressing, especially for teenagers. Support matters as much as treatment. See coping with hair loss.
  • Folk beliefs: in Chinese communities alopecia areata is sometimes called "ghost shave" (鬼剃头). It is an immune condition, not a curse or a sign of bad luck. See folk beliefs about sudden bald patches.

Common myths

  • "Alopecia areata is caused by stress alone." Stress may be a trigger in some people, but genes and the immune system are central 5.
  • "Once the hair grows back on a JAK inhibitor, you are fixed." The medicine controls the immune attack; it does not switch it off for good.
  • "Hair tonics or shampoos can treat alopecia areata." Cosmetic products can keep the scalp clean and comfortable, but they do not treat an autoimmune condition.
  • "JAK inhibitors are too dangerous for anyone." The risks are real, but for carefully selected people with severe disease, with screening and monitoring, many doctors consider the balance acceptable 7.
  • "Newer always means better." Upadacitinib is the newest of the oral options in the EU, but there is no direct comparison showing it beats the others.

Practical checklist

  • Take clear photos of every patch, eyebrows and eyelashes, with dates.
  • Note when the hair loss started, whether it has happened before, and any family history of autoimmune conditions.
  • List your medicines, health conditions, vaccines and pregnancy plans.
  • Ask the dermatologist: How severe is my alopecia areata (SALT score)? Am I a candidate for a JAK inhibitor? Which one, and why? What tests will I need, and how often? What happens if I stop?
  • Ask for the full cost, including blood tests and follow-up.
  • Keep a simple diary of side effects such as acne or infections.
  • Consider camouflage (SMP, wigs, brow products) as a parallel option, not a failure.
  • Seek support if the hair loss is affecting your mood, school or work.

Key terms

  • SALT score: the percentage of scalp hair lost; SALT 20 or less is the usual success target in trials.
  • JAK inhibitor: a medicine that blocks Janus kinase enzymes used by inflammatory signals.
  • Alopecia totalis / universalis: loss of all scalp hair / all body hair.
  • Immune privilege: the normal protection that hides growing follicles from immune attack.

Frequently asked questions

What is upadacitinib?

Upadacitinib is an oral JAK inhibitor, sold as Rinvoq, that acts mainly on the JAK1 enzyme. It is already approved for several inflammatory diseases, and in 2026 it was approved in the European Union for severe alopecia areata 2.

How well did upadacitinib work in alopecia areata trials?

In two phase 3 trials, about 45% of people on 15 mg and about 55% on 30 mg reached at least 80% scalp hair coverage after 24 weeks, compared with 1.5% to 3.4% on placebo 1.

Is upadacitinib approved for alopecia areata in Malaysia?

Rambut has not seen a Malaysian approval for this use. Registered medicines can be checked on the NPRA QUEST search 12, but whether it can be prescribed for alopecia areata is a question for a dermatologist.

What are the main side effects?

In the trials the most common were upper respiratory infections, acne, a raised muscle enzyme on blood tests and colds. JAK inhibitors also carry a class warning about serious heart events, cancer, blood clots and death 1 13.

Will the hair fall out again if I stop?

Often, yes. JAK inhibitors control the immune attack rather than switching it off, so hair loss can return after stopping. Any change should be planned with your doctor 7.

Is upadacitinib better than baricitinib or ritlecitinib?

No trial has compared them directly, so there is no reliable answer. Each has phase 3 evidence, and the choice depends on your health, age, other conditions and what is available to your doctor 7.

Can teenagers take it?

The trials included 118 adolescents aged 12 and over, and the EU approval covers people aged 12 and above with severe alopecia areata 1 2. Treatment for a teenager should be decided with a dermatologist.

Sources

  1. JAMA Dermatology (via PubMed Central). Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials, 2026. accessed 27 Oct 2026
  2. Dermatology Times. EU approves upadacitinib for severe alopecia areata as US review remains pending, 2026. accessed 27 Oct 2026
  3. American Academy of Dermatology. Alopecia areata: Overview. accessed 27 Oct 2026
  4. NIAMS (US National Institutes of Health). Alopecia areata. accessed 27 Oct 2026
  5. American Academy of Dermatology. Alopecia areata: Causes. accessed 27 Oct 2026
  6. DermNet. Alopecia areata. accessed 27 Oct 2026
  7. PubMed. Janus kinase inhibitors for alopecia areata, J Am Acad Dermatol, 2023. accessed 27 Oct 2026
  8. PubMed. Two Phase 3 Trials of Baricitinib for Alopecia Areata, N Engl J Med, 2022. accessed 27 Oct 2026
  9. PubMed. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial, Lancet, 2023. accessed 27 Oct 2026
  10. AbbVie (news release). AbbVie submits application to FDA for upadacitinib for adults and adolescents with severe alopecia areata, 28 Apr 2026. accessed 27 Oct 2026
  11. National Alopecia Areata Foundation. Phase 3 trials show strong hair growth with upadacitinib for severe alopecia areata, 21 Aug 2026. accessed 27 Oct 2026
  12. National Pharmaceutical Regulatory Agency (NPRA), Malaysia. QUEST 3+ Product Search. accessed 27 Oct 2026
  13. US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors, 2021. accessed 27 Oct 2026
  14. American Academy of Dermatology. Alopecia areata: Diagnosis and treatment. accessed 27 Oct 2026
  15. PubMed. Treatments for alopecia areata: a network meta-analysis, Cochrane Database Syst Rev, 2023. accessed 27 Oct 2026
  16. Persatuan Dermatologi Malaysia. Persatuan Dermatologi Malaysia (Dermatological Society of Malaysia). accessed 27 Oct 2026

Educational content. Not medical advice.

Related reading

Hair Loss

Alopecia areata (patchy hair loss): a clear explainer

An in-depth guide to alopecia areata (botak tompok): the immune biology, types, diagnosis and look-alikes, what to do when you find a patch, a timeline, treatment options compared with pros and risks, camouflage and coping, the Malaysian context, myths and a checklist.

Rambut editorial team ·

Hair Loss

Can alopecia areata go away on its own?

Can alopecia areata go away on its own? Often, especially small recent patches, but no one can predict it. What affects the outlook, when to wait, when to treat and how to track patches.

Rambut editorial team ·

All articles